Background on Entering Early Clinical Trials

City is a company co-founded by John Maraganore, the former CEO of Alnylam, and is building a new pipeline of therapeutics based on a next-generation RNAi platform. The company recently secured approximately $100 million in funding to accelerate its strategy of advancing its programs into early clinical trials.

Clinical Progress and Significance

City has advanced its lead program, a therapeutic for the treatment of coagulation disorders, into early human trials, and its second program, a therapeutic for the treatment of Stargardt disease, is expected to enter clinical trials soon. These therapeutics are expected to offer more precise gene silencing effects than existing therapies, potentially opening the door to personalized medicine.

Why Now?

RNAi technology has recently seen increased investor interest due to the reporting of improved safety data and efficacy. In addition, the U.S. FDA has clarified its guidelines for RNA-based therapeutics, which has encouraged companies to accelerate their entry into clinical trials.

Impact on the Industry

City's successful fundraising demonstrates that private biotech companies can secure large amounts of capital and quickly begin clinical development. This is likely to serve as a precedent for other RNAi startups seeking to raise capital.

Implications for Investors and Researchers

Investors should closely monitor the clinical progress and funding flows of RNAi platform companies, and in particular, they should reassess the risk-reward profile when early-stage companies secure large amounts of capital. Researchers will have the opportunity to expand their understanding of the mechanism of action and the scope of application of new RNAi therapeutics as clinical data become available.